EQS-News: Quantumzyme Announces Publication of Patents Supporting Sustainable Pharmaceutical Growth & Innovation

SAN DIEGO, CA - October 31, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTCQB: QTZM), a biotechnology company pioneering enzyme engineering and green chemistry solutions, is pleased to announce details regarding the World Intellectual Property Organization (WIPO) publication of its international patent application titled “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen” (Publication No. WO 2025/093935 A1).

Although the patent was published in May 2025, the company is announcing it now to highlight the Company’s ongoing progress and commitment to growth through innovation in sustainable pharmaceutical manufacturing. This announcement also reflects the company’s broader growth strategy, which centers on expanding its enzyme engineering capabilities, strengthening its intellectual property portfolio, and advancing discussions with potential global partners. The “Next Steps” outlined below represent the next phase in executing that strategy.

The company previously announced the publication of its U.S. Patent Application (U.S. Patent Application Publication No. US 2025/0146029 A1) covering related enzymatic processes. Together, these filings establish broad protection for Quantumzyme’s proprietary enzyme engineering platform in both the United States and international markets.

These publications strengthen Quantumzyme’s international intellectual property portfolio and represent a major step toward commercializing its enzymatic process for the sustainable manufacture of ibuprofen. These patents cover the company’s proprietary biocatalytic method for producing ibuprofen through an enzyme-mediated process designed to reduce chemical waste, eliminate harsh reagents, and enhance overall manufacturing efficiency.

“The publication of our patents both in the USA and internationally mark an important milestone for Quantumzyme,” stated Naveen Kulkarni, CEO of Quantumzyme Corp. “It validates the strength of our enzyme engineering technology and enhances our position for global partnerships focused on greener, more efficient pharmaceutical manufacturing. It also allows us to advance into the optimization and pilot-testing phase, and engaging with potential partners interested in sustainable and scalable API production.”

The patented ibuprofen synthesis builds on Quantumzyme’s proprietary QZyme Workbench™ platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts. This technology underpins multiple enzyme systems the company is developing for sustainable, high-efficiency production of active pharmaceutical ingredients (APIs) and specialty chemicals.

Next Steps

Quantumzyme intends to:

• Continue laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process.
• Pursue discussions with global pharmaceutical and contract manufacturing organizations (CMOs) regarding licensing or joint-development frameworks.
• File additional patent applications covering related enzymatic transformations and process improvements.

For more information and updates, please visit our website at www.quantumzymecorp.com and the Company’s profile at www.otcmarkets.com/stock/QTZM.

About Quantumzyme Corp.

Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology enables greener, more efficient global manufacturing.

Disclaimer

The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice.

Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.

Contact

Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com

View the original release on www.newmediawire.com

News Source: Quantumzyme Corp